Innovations Advanced by M&A: The First Therapy for Pompe Disease

by Hanna | May 1, 2024 | Blog Post, Innovations Advanced by M&A

This blog is another installment in our series, Innovations Advanced by M&A, which underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this series...

House Committee on Small Business Urges FTC, DOJ to Consider Consequences of Recent Merger Guidelines on Early-Stage Companies

by Hanna | Apr 25, 2024 | Blog Post

Bipartisan policymakers continue to raise concerns about the recently finalized 2023 Merger Guidelines and their impact on early-stage companies. Last week, the House Committee on Small Business wrote to the Federal Trade Commission (FTC) and Antitrust Division of the...

‘Material Differences’ & ‘Less Burden’: FTC, DOJ Signal Forthcoming Changes to Proposed HSR Rules

by Hanna | Apr 24, 2024 | Blog Post

Speaking to antitrust experts at the ABA’s 2024 Spring Antitrust Meeting, Andrew Forman, deputy assistant attorney general at the Department of Justice’s (DOJ) Antitrust division, suggested that the Federal Trade Commission (FTC) and DOJ’s forthcoming changes to the...

Innovations Advanced by M&A: A Cure for Inherited Blindness

by Hanna | Apr 18, 2024 | Blog Post, Innovations Advanced by M&A

This blog is the first installment in a series, Innovations Advanced by M&A, that underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. Across the United States’ world-class life...

FTC & DOJ Focus on ‘Nascent Competition’ Ignores Unique Market Dynamics in the Life Sciences

by Hanna | Apr 10, 2024 | Blog Post

The Federal Trade Commission (FTC) and Department of Justice (DOJ) have increasingly focused on the impact that mergers and acquisitions (M&A) in the life sciences could have on “nascent competition” – the competition that might eventually exist between...